Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Standardized activities for lay patient navigators in breast cancer care: Recommendations from a citywide implementation study.

Freund KM, Haas JS, Lemon SC, Burns White K, Casanova N, Dominici LS, Erban JK, Freedman RA, James TA, Ko NY, LeClair AM, Moy B, Parsons SK, Battaglia TA.

Cancer. 2019 Dec 15;125(24):4532-4540. doi: 10.1002/cncr.32432. Epub 2019 Aug 26.

PMID:
31449680
2.

Timeliness of Treatment Initiation in Newly Diagnosed Patients With Breast Cancer.

Dong J, Esham KS, Boehm L, Karim SA, Lin M, Mao D, Wang F, Fein D, Wang H, Studenmund C, Weidner RA, Noubary F, Freund KM, Erban JK, Parsons SK.

Clin Breast Cancer. 2019 Jul 11. pii: S1526-8209(18)30831-0. doi: 10.1016/j.clbc.2019.06.009. [Epub ahead of print]

PMID:
31439436
3.

Development of Phase-Specific Breast Cancer Survivorship Care Plans.

Boehm L, Weisberg T, Linendoll N, Damon AC, Erban JK, Parsons SK.

Clin Breast Cancer. 2019 Dec;19(6):e723-e730. doi: 10.1016/j.clbc.2019.05.017. Epub 2019 Jun 5.

PMID:
31278019
4.

Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.

Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, Wahner-Hendrickson AE, Forero A, Anders C, Wulf GM, Dillon P, Lynce F, Zarwan C, Erban JK, Zhou Y, Buerstatte N, Graham JR, Arora S, Dezube BJ, Telli ML.

JAMA Oncol. 2019 Jun 13. doi: 10.1001/jamaoncol.2019.1029. [Epub ahead of print]

5.

Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.

Upshaw JN, Ruthazer R, Miller KD, Parsons SK, Erban JK, O'Neill AM, Demissei B, Sledge G, Wagner L, Ky B, Kent DM.

Clin Breast Cancer. 2019 Aug;19(4):259-267.e1. doi: 10.1016/j.clbc.2019.04.012. Epub 2019 May 2.

PMID:
31175052
6.

Vitamin D supplementation for prevention of cancer: The D2d cancer outcomes (D2dCA) study.

Chatterjee R, Erban JK, Fuss P, Dolor R, LeBlanc E, Staten M, Sheehan P, Pittas A; D2d Research Group.

Contemp Clin Trials. 2019 Jun;81:62-70. doi: 10.1016/j.cct.2019.04.015. Epub 2019 Apr 29.

PMID:
31048088
7.

Efficacy and Effectiveness Too Trials: Clinical Trial Designs to Generate Evidence on Efficacy and on Effectiveness in Wide Practice.

Selker HP, Eichler HG, Stockbridge NL, McElwee NE, Dere WH, Cohen T, Erban JK, Seyfert-Margolis VL, Honig PK, Kaitin KI, Oye KA, D'Agostino RB Sr.

Clin Pharmacol Ther. 2019 Apr;105(4):857-866. doi: 10.1002/cpt.1347. Epub 2019 Feb 12.

8.

Evolution of modern breast cancer treatment: when less is more.

Erban JK.

Gland Surg. 2018 Aug;7(4):347-349. doi: 10.21037/gs.2018.07.06. No abstract available.

9.

Timing of Metastasis in Breast Cancer.

Schwartz RS, Erban JK.

N Engl J Med. 2017 Jun 22;376(25):2486-2488. doi: 10.1056/NEJMcibr1701388. No abstract available.

PMID:
28636861
10.

Neoadjuvant therapy for treatment of breast cancer: the way forward, or simply a convenient option for patients?

Chatterjee A, Erban JK.

Gland Surg. 2017 Feb;6(1):119-124. doi: 10.21037/gs.2016.08.07.

11.

Rapid Change in Mental Status in a Patient with Hypereosinophilia.

Wang H, Erban JK.

Case Rep Hematol. 2017;2017:6936709. doi: 10.1155/2017/6936709. Epub 2017 Jan 10.

12.

Weight Management: Perception, Interest, and Preferences in Adult Cancer Survivors.

Zhang FF, Meagher S, Koch-Weser S, Singer M, Dhaundiyal G, Erban J, Saltzman E.

Clin J Oncol Nurs. 2017 Feb 1;21(1):65-71. doi: 10.1188/17.CJON.65-71.

13.

Promoting High-Quality Cancer Care and Equity Through Disciplinary Diversity in Team Composition.

Parsons SK, Fineberg IC, Lin M, Singer M, Tang M, Erban JK.

J Oncol Pract. 2016 Nov;12(11):1141-1147. Epub 2016 Oct 31.

PMID:
27577618
14.

Secondary pulmonary alveolar proteinosis in hematologic malignancies.

Chaulagain CP, Pilichowska M, Brinckerhoff L, Tabba M, Erban JK.

Hematol Oncol Stem Cell Ther. 2014 Dec;7(4):127-35. doi: 10.1016/j.hemonc.2014.09.003. Epub 2014 Oct 6. Review.

15.

A proposal for integrated efficacy-to-effectiveness (E2E) clinical trials.

Selker HP, Oye KA, Eichler HG, Stockbridge NL, Mehta CR, Kaitin KI, McElwee NE, Honig PK, Erban JK, D'Agostino RB.

Clin Pharmacol Ther. 2014 Feb;95(2):147-53. doi: 10.1038/clpt.2013.177. Epub 2013 Sep 23.

16.

Invasive breast cancer.

Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Sachdev J, Smith ML, Somlo G, Ward JH, Wolff AC, Zellars R; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Feb;9(2):136-222. No abstract available.

PMID:
21310842
17.

Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial.

Ganz PA, Land SR, Geyer CE Jr, Cecchini RS, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff JA, Vogel VG, Erban JK, Livingston RB, Perez EA, Mamounas EP, Wolmark N, Swain SM.

J Clin Oncol. 2011 Mar 20;29(9):1110-6. doi: 10.1200/JCO.2010.29.7689. Epub 2011 Feb 7.

18.

Breast cancer: noninvasive and special situations.

Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Somlo G, Topham NS, Ward JH, Winer EP, Wolff AC.

J Natl Compr Canc Netw. 2010 Oct;8(10):1182-207. No abstract available.

PMID:
20971842
19.

Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.

Swain SM, Jeong JH, Geyer CE Jr, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff J, Vogel VG, Erban JK, Rastogi P, Livingston RB, Perez EA, Mamounas EP, Land SR, Ganz PA, Wolmark N.

N Engl J Med. 2010 Jun 3;362(22):2053-65. doi: 10.1056/NEJMoa0909638.

20.

Breast cancer. Clinical practice guidelines in oncology.

Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault RL, Topham NS, Ward JH, Winer EP, Wolff AC; NCCN Breast Cancer Clinical Practice Guidelines Panel.

J Natl Compr Canc Netw. 2009 Feb;7(2):122-92. Review. No abstract available.

PMID:
19200416
22.

Lack of uniform diagnostic criteria for inflammatory breast cancer limits interpretation of treatment outcomes: a systematic review.

Kim T, Lau J, Erban J.

Clin Breast Cancer. 2006 Dec;7(5):386-95. Review. Erratum in: Clin Breast Cancer. 2008 Feb;8(1):25.

PMID:
17239263
23.

Autoimmune hemolytic anemia in patients with liver transplants for primary biliary cirrhosis: Three case reports and a review of the literature.

Retana AK, Kaplan MM, Erban JK.

Am J Gastroenterol. 2007 Jan;102(1):197-200. Epub 2006 Oct 13. Review.

PMID:
17037996
24.

Terri Schiavo: rest in peace.

Erban J.

CMAJ. 2006 Sep 12;175(6):621; author reply 621-4. No abstract available.

25.

On the toxicity of chemotherapy for breast cancer--the need for vigilance.

Erban JK, Lau J.

J Natl Cancer Inst. 2006 Aug 16;98(16):1096-7. No abstract available.

PMID:
16912256
26.

Private health insurance needs consent.

Erban J.

CMAJ. 2006 Jul 4;175(1):62-3. No abstract available.

27.

Letrozole or tamoxifen in early breast cancer.

Erban JK.

N Engl J Med. 2006 Apr 6;354(14):1528-30; author reply 1528-30. No abstract available.

PMID:
16602148
28.
29.

Patients beware.

Erban J.

CMAJ. 2005 Aug 30;173(5):465-6. No abstract available.

30.

Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.

Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM.

J Clin Oncol. 2005 Aug 20;23(24):5542-51.

PMID:
16110015
31.

Images in cardiovascular medicine. Primary lymphoma of the heart.

Kuvin J, Parikh N, Salomon R, Tischler A, Daoust P, Arshanskiy Y, Coyner K, Carpino P, Pandian NG, Kimmelstiel C, Foote C, Erban J, Rastegar H.

Circulation. 2005 Jul 5;112(1):e5-6. No abstract available.

PMID:
15998689
32.

Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer.

Gradishar WJ, Wedam SB, Jahanzeb M, Erban J, Limentani SA, Tsai KT, Olsen SR, Swain SM.

Ann Oncol. 2005 Aug;16(8):1297-304. Epub 2005 May 19.

PMID:
15905305
33.

C. difficile: will lessons be learned?

Erban J.

CMAJ. 2005 Apr 26;172(9):1161. No abstract available.

34.

Informing the public.

Erban J.

CMAJ. 2004 Aug 17;171(4):309. No abstract available.

35.

Phase II study of interferon gamma in malignant carcinoid tumors (E9292): a trial of the Eastern Cooperative Oncology Group.

Stuart K, Levy DE, Anderson T, Axiotis CA, Dutcher JP, Eisenberg A, Erban JK, Benson III AB; Eastern Cooperative Oncology Group.

Invest New Drugs. 2004 Jan;22(1):75-81.

PMID:
14707497
37.

Screening for the risk for bleeding or thrombosis.

Eckman MH, Erban JK, Singh SK, Kao GS.

Ann Intern Med. 2003 Feb 4;138(3):W15-24. Review.

PMID:
12558384
39.

Survival impact of tamoxifen use for breast cancer risk reduction: projections from a patient-specific Markov model.

Col NF, Goldberg RJ, Orr RK, Erban JK, Fortin JM, Chlebowski RT.

Med Decis Making. 2002 Sep-Oct;22(5):386-93.

PMID:
12365480
40.
41.
42.

Testing for factor V Leiden in patients with pulmonary or venous thromboembolism: a cost-effectiveness analysis.

Eckman MH, Singh SK, Erban JK, Kao G.

Med Decis Making. 2002 Mar-Apr;22(2):108-24.

PMID:
11958494
43.

Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation.

Narayanasami U, Kanteti R, Morelli J, Klekar A, Al-Olama A, Keating C, O'Connor C, Berkman E, Erban JK, Sprague KA, Miller KB, Schenkein DP.

Blood. 2001 Oct 1;98(7):2059-64.

PMID:
11567990
44.

Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk.

Col NF, Hirota LK, Orr RK, Erban JK, Wong JB, Lau J.

J Clin Oncol. 2001 Apr 15;19(8):2357-63. Review.

PMID:
11304788
45.

Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882).

Pandya KJ, Yeap BY, Weiner LM, Krook JE, Erban JK, Schinella RA, Davis TE.

Am J Clin Oncol. 2001 Feb;24(1):43-6.

PMID:
11232948
46.

The importance of local-regional radiotherapy with conventional or high-dose chemotherapy in the management of breast cancer patients with > or = 10 positive axillary nodes.

Jabro G, Wazer DE, Ruthazer R, Lum R, Sklar N, Goldman D, Enegess D, Erban J.

Int J Radiat Oncol Biol Phys. 1999 May 1;44(2):273-80.

PMID:
10760419
47.

Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group.

Stadtmauer EA, O'Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, Brodsky I, Martino S, Lazarus HM, Erban JK, Sickles C, Glick JH.

N Engl J Med. 2000 Apr 13;342(15):1069-76.

48.

Hepatic perfusion changes in patients with cirrhosis indices of hepatic arterial blood flow.

Koranda P, Myslivecek M, Erban J, Seidlová V, Husák V.

Clin Nucl Med. 1999 Jul;24(7):507-10.

PMID:
10402004
49.

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.

Valero V, Jones SE, Von Hoff DD, Booser DJ, Mennel RG, Ravdin PM, Holmes FA, Rahman Z, Schottstaedt MW, Erban JK, Esparza-Guerra L, Earhart RH, Hortobagyi GN, Burris HA 3rd.

J Clin Oncol. 1998 Oct;16(10):3362-8.

PMID:
9779713
50.

Factors determining outcome for breast-conserving irradiation with margin-directed dose escalation to the tumor bed.

Wazer DE, Schmidt-Ullrich RK, Ruthazer R, Schmid CH, Graham R, Safaii H, Rothschild J, McGrath J, Erban JK.

Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):851-8.

PMID:
9531370

Supplemental Content

Support Center